Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Updated 2017 //http://www.ginasthma.org.http://www.ginasthma.org
Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43: 343-373.
Palomares O, Sanchez-Ramon S, Davila I et al. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Int. J. Mol. Sci., 2017, 18: 1328.
Samitas K, DelimpouraV, Zervas E, Gaga M. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev, 2015, 24: 594–601.
Roth M, Zhong J, Zumkeller C et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS ONE, 2013, 8: e56015.
Redhu NS, Shan L, Al-Subait D et al. IgE induces proliferation in human airway smooth muscle cells: Role of MAPK and STAT3 pathways. Allergy Asthma Clin. Immunol, 2013, 9: 41.
Черняк Б.А., Воржева И.И. Эозинофилы и аллергия. Российский Аллергологический Журнал, 2013, 4: 3-12.
Cottini M, Lombardi C, Micheletto C. Small airway dysfunction and bronchial asthma control: the state of the art. Asthma Research and Practice, 2015, 1: 13.
Российское респираторное общество, Педиатрическое респираторное общество. Клинические рекомендации по диагностике и лечению бронхиальной астмы 2016. http:// spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/http://spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/
Княжеская Н.П., Белевский А.С., Осипова Г.Л., Фабрика М.П. Таргетная терапия бронхиальной астмы: в фокусе внимания омализумаб. Практическая пульмонология, 2015, 2: 32-38.
Abraham I, Alhossan A, Lee C S et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy, 2016, 71: 593–610.
Riccio AM, Mauri P, De Ferrari L et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy, 2017, 7: 6.
Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration, 2012, 83: 520–528.
Tajiri T, Niimi A, Matsumoto H et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol, 2014, 113: 470-475.
Ильина Н.И., Намазова-Баранова Л.С., Емельянов А.В. и др. Алгоритм назначения иммунобиологических препаратов при тяжелой атопической бронхиальной астме в России (Согласительный документ). Российский Аллергологический Журнал, 2014, 4: 26-27.